RxDoctor Payments Data

Tina Watkins, NP

Nurse Practitioner · Norfolk, VANPI 1891140422

Payments from drug & device makers

$4,583in general payments, 2019–2025

Across 219 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$502
  • Johnson & Johnson$461
  • Sanofi$393
  • E.r. Squibb & Sons, L.L.C.$230
  • Lilly USA, LLC$230
  • plus $936 from 13 others

What the payments were for

  • Food & beverage$4,23592%
  • Education$3488%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,583 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$163,527
Medicare patients
764
Services billed
7,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa21$414,592
Humira(Cf) PenAdalimumab16$235,524
Dupixent PenDupilumab34$146,429
OtezlaApremilast21$107,738
Dupixent SyringeDupilumab26$93,919
Enbrel SureclickEtanercept12$84,648
Clobetasol Propionate64$2,917
Betamethasone Dipropionate62$2,725
Fluorouracil35$2,690
Ketoconazole124$2,054
Doxycycline Hyclate83$914
Triamcinolone Acetonide82$879
Clindamycin Phosphate17$818
Fluocinolone Acetonide22$752
ValacyclovirValacyclovir Hcl20$740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$502$107,73821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →